Characterization of a New Class of Polycyclic RSV Inhibitors

Luttick, Angela; Lin, Bo; Morton, Catherine; Tucker, Simon P.; Bond, S; Draffan, Alistair G.; Lambert, John; Lim, C; Mitchell, Jeffrey P.; Sanford, V

doi:10.1016/j.antiviral.2007.01.103

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another fusion inhibitor is RS 637, also known as VP14637 (RSVCO, Inc., Gaithersburg, MD); the compound is in late-stage preclinical development. BTA9881 is an F-protein inhibitor under phase I clinical development by Biota/MedImmune (131). siRNAs (Alnylam Pharmaceuticals, Cambridge, MA) have also been developed for aerosol delivery (45); ALN-RSV01 is presently undergoing phase II testing in adults experimentally infected with RSV.…”

Section: Rsvmentioning

confidence: 99%

Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances

2008

View full text Add to dashboard Cite

SUMMARY Though several antivirals have been developed and marketed to treat influenza virus infections, the development of antiviral agents with clinical activity against other respiratory viruses has been more problematic. Here we review the epidemiology of respiratory viral infections in immunocompetent and immunocompromised hosts, examine the evidence surrounding the currently available antivirals for respiratory viral infections other than influenza, highlight those that are in the pipeline, and discuss the hurdles for development of such agents.

show abstract

Section: Rsvmentioning

confidence: 99%